Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Cuu Long Pharmaceutical

HOSE:DCL
Snowflake Description

Mediocre balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DCL
HOSE
₫1,023B
Market Cap
  1. Home
  2. VN
  3. Pharmaceuticals & Biotech
Company description

Cuu Long Pharmaceutical Joint Stock Company manufactures and sells pharmaceutical products primarily in Vietnam. The last earnings update was 70 days ago. More info.


Add to Portfolio Compare Print
  • Cuu Long Pharmaceutical has significant price volatility in the past 3 months.
DCL Share Price and Events
7 Day Returns
-9.5%
HOSE:DCL
0.7%
VN Pharmaceuticals
-0.8%
VN Market
1 Year Returns
-4.8%
HOSE:DCL
-22%
VN Pharmaceuticals
-31.6%
VN Market
DCL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cuu Long Pharmaceutical (DCL) -9.5% -14.3% -35.7% -4.8% -23.2% 7.5%
VN Pharmaceuticals 0.7% -14.3% -14.3% -22% -21.6% 28.1%
VN Market -0.8% -24.1% -30% -31.6% -2.9% 32.7%
1 Year Return vs Industry and Market
  • DCL outperformed the Pharmaceuticals industry which returned -22% over the past year.
  • DCL outperformed the Market in Viet Nam which returned -31.6% over the past year.
Price Volatility
DCL
Industry
5yr Volatility vs Market

Value

 Is Cuu Long Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cuu Long Pharmaceutical. This is due to cash flow or dividend data being unavailable. The share price is ₫18000.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cuu Long Pharmaceutical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cuu Long Pharmaceutical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
HOSE:DCL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in VND ₫1,556.74
HOSE:DCL Share Price ** HOSE (2020-03-31) in VND ₫18000
Viet Nam Pharmaceuticals Industry PE Ratio Median Figure of 12 Publicly-Listed Pharmaceuticals Companies 13.3x
Viet Nam Market PE Ratio Median Figure of 386 Publicly-Listed Companies 7.84x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cuu Long Pharmaceutical.

HOSE:DCL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= HOSE:DCL Share Price ÷ EPS (both in VND)

= 18000 ÷ 1,556.74

11.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cuu Long Pharmaceutical is good value based on earnings compared to the VN Pharmaceuticals industry average.
  • Cuu Long Pharmaceutical is overvalued based on earnings compared to the Viet Nam market.
Price based on expected Growth
Does Cuu Long Pharmaceutical's expected growth come at a high price?
Raw Data
HOSE:DCL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 11.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Asia Pharmaceuticals Industry PEG Ratio Median Figure of 156 Publicly-Listed Pharmaceuticals Companies 1.39x
Viet Nam Market PEG Ratio Median Figure of 56 Publicly-Listed Companies 0.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cuu Long Pharmaceutical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cuu Long Pharmaceutical's assets?
Raw Data
HOSE:DCL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in VND ₫14,725.76
HOSE:DCL Share Price * HOSE (2020-03-31) in VND ₫18000
Viet Nam Pharmaceuticals Industry PB Ratio Median Figure of 12 Publicly-Listed Pharmaceuticals Companies 1.83x
Viet Nam Market PB Ratio Median Figure of 405 Publicly-Listed Companies 0.85x
HOSE:DCL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= HOSE:DCL Share Price ÷ Book Value per Share (both in VND)

= 18000 ÷ 14,725.76

1.22x

* Primary Listing of Cuu Long Pharmaceutical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cuu Long Pharmaceutical is good value based on assets compared to the VN Pharmaceuticals industry average.
X
Value checks
We assess Cuu Long Pharmaceutical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Cuu Long Pharmaceutical has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cuu Long Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cuu Long Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.3%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cuu Long Pharmaceutical expected to grow at an attractive rate?
  • Unable to compare Cuu Long Pharmaceutical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Cuu Long Pharmaceutical's earnings growth to the Viet Nam market average as no estimate data is available.
  • Unable to compare Cuu Long Pharmaceutical's revenue growth to the Viet Nam market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
HOSE:DCL Future Growth Rates Data Sources
Data Point Source Value (per year)
Asia Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 19.3%
Asia Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 10.6%
Viet Nam Market Earnings Growth Rate Market Cap Weighted Average 16%
Viet Nam Market Revenue Growth Rate Market Cap Weighted Average 18.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
HOSE:DCL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in VND Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
HOSE:DCL Future Estimates Data
Date (Data in VND Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
HOSE:DCL Past Financials Data
Date (Data in VND Millions) Revenue Cash Flow Net Income *
2019-12-31 752,014 75,575 88,474
2019-09-30 768,082 120,163 7,858
2019-06-30 776,542 70,655 -534
2019-03-31 786,329 40,939 3,505
2018-12-31 804,180 -63,280 12,535
2018-09-30 781,391 -73,542 22,524
2018-06-30 778,219 -45,636 40,199
2018-03-31 799,906 1,710 64,378
2017-12-31 765,342 49,813 71,915
2017-09-30 760,225 34,597 89,604
2017-06-30 750,782 51,077 87,895
2017-03-31 713,780 23,886 82,365

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Cuu Long Pharmaceutical is high growth as no earnings estimate data is available.
  • Unable to determine if Cuu Long Pharmaceutical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
HOSE:DCL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Cuu Long Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

HOSE:DCL Future Estimates Data
Date (Data in VND Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
HOSE:DCL Past Financials Data
Date (Data in VND Millions) EPS *
2019-12-31 1,556.74
2019-09-30 138.26
2019-06-30 -9.40
2019-03-31 61.67
2018-12-31 220.55
2018-09-30 396.61
2018-06-30 709.40
2018-03-31 1,138.69
2017-12-31 1,274.72
2017-09-30 1,590.61
2017-06-30 1,560.29
2017-03-31 1,462.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cuu Long Pharmaceutical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Cuu Long Pharmaceutical's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Cuu Long Pharmaceutical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Asia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cuu Long Pharmaceutical has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cuu Long Pharmaceutical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cuu Long Pharmaceutical's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cuu Long Pharmaceutical's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Cuu Long Pharmaceutical's 1-year earnings growth exceeds its 5-year average (605.8% vs -8.7%)
  • Cuu Long Pharmaceutical's earnings growth has exceeded the VN Pharmaceuticals industry average in the past year (605.8% vs 6%).
Earnings and Revenue History
Cuu Long Pharmaceutical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cuu Long Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

HOSE:DCL Past Revenue, Cash Flow and Net Income Data
Date (Data in VND Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 752,014.23 88,473.69 174,406.63
2019-09-30 768,082.49 7,857.95 178,943.37
2019-06-30 776,541.55 -534.10 182,090.91
2019-03-31 786,329.28 3,505.05 191,895.07
2018-12-31 804,179.61 12,534.55 197,608.41
2018-09-30 781,390.79 22,523.93 195,377.50
2018-06-30 778,219.09 40,198.73 181,655.64
2018-03-31 799,905.60 64,377.65 169,835.08
2017-12-31 765,341.80 71,914.69 161,942.18
2017-09-30 760,225.46 89,603.73 136,163.88
2017-06-30 750,782.12 87,895.11 145,628.77
2017-03-31 713,780.10 82,365.46 139,424.71
2016-12-31 737,805.98 88,148.74 132,399.81
2016-09-30 719,328.75 76,366.18 138,489.68
2016-06-30 707,004.43 72,878.26 132,671.98
2016-03-31 704,040.55 69,397.90 126,780.54
2015-12-31 669,564.69 61,620.42 117,034.13
2015-09-30 680,330.03 35,780.67 143,630.25
2015-06-30 676,775.91 36,443.32 145,400.07
2015-03-31 679,589.75 30,744.06 160,767.18
2015-01-01 709,564.63 29,700.12 178,474.28
2014-09-30 697,087.46 37,233.77 165,856.32
2014-06-30 701,726.43 35,371.81 159,401.02
2014-03-31 699,492.91 37,946.28 146,317.54
2014-01-01 674,570.15 30,292.41 138,451.58
2013-09-30 644,140.29 37,079.58 117,320.90
2013-06-30 638,027.01 35,854.84 111,925.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Cuu Long Pharmaceutical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • It is difficult to establish if Cuu Long Pharmaceutical has efficiently used its assets last year compared to the VN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • Cuu Long Pharmaceutical's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Cuu Long Pharmaceutical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cuu Long Pharmaceutical has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cuu Long Pharmaceutical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cuu Long Pharmaceutical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cuu Long Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cuu Long Pharmaceutical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cuu Long Pharmaceutical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cuu Long Pharmaceutical Company Filings, last reported 3 months ago.

HOSE:DCL Past Debt and Equity Data
Date (Data in VND Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 884,422.48 739,945.47 853,013.60
2019-09-30 805,427.33 766,519.96 717,861.48
2019-06-30 799,959.84 763,305.24 675,558.13
2019-03-31 802,439.06 778,613.60 675,855.70
2018-12-31 805,126.64 835,126.30 653,093.81
2018-09-30 799,643.05 849,982.84 578,826.90
2018-06-30 802,103.02 833,555.82 617,596.69
2018-03-31 876,218.91 770,713.81 701,418.04
2017-12-31 791,768.58 296,324.32 244,319.97
2017-09-30 768,731.46 140,478.24 139,251.76
2017-06-30 753,113.90 352,524.79 357,614.44
2017-03-31 681,383.77 298,740.60 234,111.36
2016-12-31 656,647.14 116,142.15 217,111.17
2016-09-30 620,928.88 106,074.19 209,552.49
2016-06-30 607,585.65 144,297.66 213,357.41
2016-03-31 586,873.12 133,853.01 208,674.14
2015-12-31 567,498.40 148,170.85 213,248.70
2015-09-30 546,663.60 218,138.85 203,680.38
2015-06-30 335,629.22 164,594.75 2,066.92
2015-03-31 318,220.52 175,763.27 3,468.49
2015-01-01 305,623.27 219,455.56 18,363.03
2014-09-30 307,527.32 252,830.20 20,659.85
2014-06-30 297,009.36 254,075.41 7,297.11
2014-03-31 291,527.42 254,142.77 15,102.40
2014-01-01 279,974.11 251,651.20 18,530.89
2013-09-30 276,344.51 306,985.15 11,605.12
2013-06-30 267,688.51 315,030.88 9,361.13
  • Cuu Long Pharmaceutical's level of debt (83.7%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (71.8% vs 83.7% today).
  • Debt is not well covered by operating cash flow (10.2%, less than 20% of total debt).
  • Cuu Long Pharmaceutical earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Cuu Long Pharmaceutical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cuu Long Pharmaceutical has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cuu Long Pharmaceutical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cuu Long Pharmaceutical dividends.
If you bought ₫2,000 of Cuu Long Pharmaceutical shares you are expected to receive ₫0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cuu Long Pharmaceutical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cuu Long Pharmaceutical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
HOSE:DCL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Viet Nam Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 4.4%
Viet Nam Market Average Dividend Yield Market Cap Weighted Average of 240 Stocks 5.2%
Viet Nam Minimum Threshold Dividend Yield 10th Percentile 3.7%
Viet Nam Bottom 25% Dividend Yield 25th Percentile 5.8%
Viet Nam Top 25% Dividend Yield 75th Percentile 14.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

HOSE:DCL Future Dividends Estimate Data
Date (Data in ₫) Dividend per Share (annual) Avg. No. Analysts
HOSE:DCL Past Annualized Dividends Data
Date (Data in ₫) Dividend per share (annual) Avg. Yield (%)
2020-01-21 0.000 0.000
2019-10-30 0.000 0.000
2019-08-26 0.000 0.000
2019-07-29 0.000 0.000
2019-04-26 0.000 0.000
2019-03-15 0.000 0.000
2019-01-29 0.000 0.000
2018-05-31 500.000 4.188
2015-11-10 0.000 0.000
2015-07-29 0.000 0.000
2015-07-28 0.000 0.000
2015-05-07 0.000 0.000
2015-03-11 0.000 0.000
2015-02-11 0.000 0.000
2014-03-31 214.286 1.740
2014-02-10 214.286 1.896
2012-05-02 714.286 16.410
2011-11-08 714.286 14.892
2011-02-09 714.286 10.846

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cuu Long Pharmaceutical has not reported any payouts.
  • Unable to verify if Cuu Long Pharmaceutical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cuu Long Pharmaceutical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cuu Long Pharmaceutical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cuu Long Pharmaceutical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 3.7%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cuu Long Pharmaceutical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cuu Long Pharmaceutical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cuu Long Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Nguyen Thi Nguyet
TENURE AS CEO 0.6 years
CEO Bio

Ms. Nguyen Thi Minh Nguyet is the Founder, Chief Executive Officer, Vice Chairman and Member of Management Board at F.I.T Investment Joint Stock Company. Ms. Nguyen is responsible for successful operations of F.I.T Investment Joint Stock Company in long term and middle term. Ms. Nguyen is also accountable for Accounts, Finance and Human Resource Operation. She has a great contribution for establishing and growing of FIT. Before founding FIT, she has 16 year experience in Mekong Automobile corporation and Shell Gas, where she worked in finance, trade and human resource fields. She has been Chief Executive Officer of Cuu Long Pharmaceutical Joint Stock Company since August 30, 2019 and its Deputy Chairwoman of the Board of Directors since March 14, 2015. Ms. Nguyen holds Bachelor’s Degree in Russian and Account and an MBA degree at National Economics University.

CEO Compensation
  • Insufficient data for Nguyen Thi to compare compensation growth.
  • Insufficient data for Nguyen Thi to establish whether their remuneration is reasonable compared to companies of similar size in .
Management Team Tenure

Average tenure of the Cuu Long Pharmaceutical management team in years:

1.6
Average Tenure
  • The average tenure for the Cuu Long Pharmaceutical management team is less than 2 years, this suggests a new team.
Management Team

Nguyen Thi Nguyet

TITLE
Deputy Chairman of the Board of Directors & CEO
TENURE
0.6 yrs

Trinh Khanh

TITLE
Deputy CEO & CFO
TENURE
1.7 yrs

Tran Nga

TITLE
Chief Accountant
TENURE
1.8 yrs

Luu Minh

TITLE
Deputy Chief Executive Officer
TENURE
4.8 yrs

Ba Nguyen

TITLE
Deputy Chief Executive Officer
TENURE
1.3 yrs

Philip Dao

TITLE
Deputy Chief Executive Officer

Bich Nguyen

TITLE
Secretary of Board of Directors
TENURE
1.6 yrs
Board of Directors Tenure

Average tenure of the Cuu Long Pharmaceutical board of directors in years:

3
Average Tenure
  • The tenure for the Cuu Long Pharmaceutical board of directors is about average.
Board of Directors

Nguyen Van Sang

TITLE
Chairman of the Board
TENURE
3 yrs

Nguyen Thi Nguyet

TITLE
Deputy Chairman of the Board of Directors & CEO
TENURE
5 yrs

Phi Truong

TITLE
Head of Board of Supervisors

Duong Nguyet

TITLE
Director
TENURE
3 yrs

Do Cao

TITLE
Director
TENURE
3 yrs

Dung Kieu Huu

TITLE
Director
TENURE
1.8 yrs

Vu Hoai

TITLE
Member of the Board of Supervisors
TENURE
3.2 yrs

Hoa Thi Phan

TITLE
Supervisor
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₫) Value (₫)
X
Management checks
We assess Cuu Long Pharmaceutical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cuu Long Pharmaceutical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Cuu Long Pharmaceutical Joint Stock Company manufactures and sells pharmaceutical products primarily in Vietnam. The company offers analgesic, anti-biotic, anti-histamine, anti-inflammatory, anti-virus, cardiovascular, contraceptive, corticosteroid, cough, dermatology, erectile, dysfunction, gastrointestinal, musculoskeletal, tonic, and vitamin medicines, as well as empty capsules. It also provides medical equipment, such as needles, infusion sets, and syringes. The company is headquartered in Vinh Long, Vietnam. Cuu Long Pharmaceutical Joint Stock Company is a subsidiary of F.I.T Group Joint Stock Company.

Details
Name: Cuu Long Pharmaceutical Joint Stock Company
DCL
Exchange: HOSE
Founded:
₫1,022,990,832,000
56,832,824
Website: http://www.pharimexco.com.vn
Address: Cuu Long Pharmaceutical Joint Stock Company
No. 150 - 14/9 Street,
Ward 5,
Vinh Long,
Vietnam
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
HOSE DCL Common Shares Ho Chi Minh Stock Exchange VN VND 17. Sep 2008
Number of employees
Current staff
Staff numbers
0
Cuu Long Pharmaceutical employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 16:14
End of day share price update: 2020/03/31 00:00
Last estimates confirmation: 2018/01/30
Last earnings filing: 2020/01/21
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.